Related references
Note: Only part of the references are listed.Current status of antiangiogenic therapies for glioblastomas
Isabel Arrillaga-Romany et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2014)
Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology)
Riccardo Soffietti et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials
Kelong Han et al.
NEURO-ONCOLOGY (2014)
Association of matrix metalloproteinase 2 plasma level with response and survival in patients treated with bevacizumab for recurrent high-grade glioma
Emeline Tabouret et al.
NEURO-ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial
Evanthia Galanis et al.
CLINICAL CANCER RESEARCH (2013)
Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy
Olivier L. Chinot et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2013)
Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Retrospective Analysis of Bevacizumab in Combination with Ifosfamide, Carboplatin, and Etoposide in Patients with Second Recurrence of Glioblastoma
Yoshiki Arakawa et al.
NEUROLOGIA MEDICO-CHIRURGICA (2013)
Angiogenesis in Glioblastoma
Sunit Das et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges
Gazanfar Rahmathulla et al.
ONCOTARGETS AND THERAPY (2013)
A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma
Michele Cecchi et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY (2013)
A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy
Soren Moller et al.
ACTA ONCOLOGICA (2012)
Bevacizumab and daily temozolomide for recurrent glioblastoma
Annick Desjardins et al.
CANCER (2012)
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab na⟨ve, recurrent glioblastoma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy
David A. Reardon et al.
CANCER (2011)
Approval denied by the European Medicines Agency (EMA) for bevacizumab in the treatment of high-grade glioma recurrence: a good idea or a grave error?
Carmen Balana et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2011)
Transdifferentiation of glioblastoma cells into vascular endothelial cells
Yasushi Soda et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A Phase 2 Trial of Single-Agent Bevacizumab Given in an Every-3-Week Schedule for Patients With Recurrent High-Grade Gliomas
Jeffrey J. Raizer et al.
CANCER (2010)
Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme
Alessandra B. Francesconi et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2010)
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells
Lucia Ricci-Vitiani et al.
NATURE (2010)
Glioblastoma stem-like cells give rise to tumour endothelium
Rong Wang et al.
NATURE (2010)
Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma
Wenting Wu et al.
NEURO-ONCOLOGY (2010)
Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme
Joost J. C. Verhoeff et al.
BMC CANCER (2009)
Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study
D. A. Reardon et al.
BRITISH JOURNAL OF CANCER (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
R. M. Zuniga et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model
Kristoph Jahnke et al.
NEURO-ONCOLOGY (2009)
Bevacizumab and chemotherapy for recurrent glioblastoma A single-institution experience
P. L. Nghiemphu et al.
NEUROLOGY (2009)
FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen et al.
ONCOLOGIST (2009)
Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors
Felix Bokstein et al.
CANCER (2008)
HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion
Rose Du et al.
CANCER CELL (2008)
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety
Tyler Y. Kang et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases
Sheikh A. Ali et al.
JOURNAL OF NEUROSURGERY (2008)
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Kathleen R. Lamborn et al.
NEURO-ONCOLOGY (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Combining Bevacizumab with Temozolomide Increases the Antitumor Efficacy of Temozolomide in a Human Glioblastoma Orthotopic Xenograft Model
Veronique Mathieu et al.
NEOPLASIA (2008)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Karla V. Ballman et al.
NEURO-ONCOLOGY (2007)
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
WB Pope et al.
NEUROLOGY (2006)
Platelet-derived growth factor (PDGF) and glial tumorigenesis
AH Shih et al.
CANCER LETTERS (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
N Ferrara et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1
LX Liu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2002)
A comparison of treatment results for recurrent malignant gliomas
C Nieder et al.
CANCER TREATMENT REVIEWS (2000)
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption
JL Rubenstein et al.
NEOPLASIA (2000)
Share Paper
